Can a standard HIV pill rescue those who got infected on Long-Acting PrEP?
NCT ID NCT06485154
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a daily combination pill (TLD) as first-line HIV treatment for 100 people who became infected with HIV despite receiving long-acting cabotegravir PrEP in the past year. Researchers will check if the pill can suppress the virus to undetectable levels after 6 months. The goal is to find a reliable treatment option for this specific group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir, Lamivudine, and Dolutegravir (TLD) combination pill
What this could lead to
If successful, this could confirm that a standard daily HIV pill works well for people who get infected despite using long-acting PrEP, offering a reliable treatment option.
What could go wrong
This is a small, single-arm study with only 100 participants, so results may not apply to everyone. Drug resistance from prior PrEP use could reduce effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Africa Health Research Institute (AHRI)
RECRUITINGDurban, KwaZulu-Natal, 3935, South Africa
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Desmond Tutu Health Foundation
RECRUITINGCape Town, Western Cape, 7925, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Ezintsha, a division of Wits Health Consortium
RECRUITINGJohannesburg, Gauteng, 2193, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact